TY  - JOUR
AU  - del Carmen Alamo, Ma
AU  - Ochenduszko, Sebastian
AU  - Crespo, Guillermo
AU  - Corral, Monica
AU  - Oramas, Juana
AU  - Sancho, Pilar
AU  - Medina, Javier
AU  - Garicano, Fernando
AU  - Lopez, Pedro
AU  - Campos Balea, Begona
AU  - Rodriguez Garzotto, Analia
AU  - Munoz-Couselo, Eva
PY  - 2021
DO  - 10.2147/OTT.S325208
SN  - 1178-6930
UR  - https://hdl.handle.net/10668/26599
T2  - Oncotargets and therapy
AB  - Background: The combination of BRAF and MEK inhibitors delays the onset of resistance and provides more sustained and dramatic responses in comparison with a BRAF inhibitor in monotherapy. The objective of the study was to evaluate the effectiveness...
LA  - en
PB  - Dove medical press ltd
KW  - vemurafenib
KW  - cobimetinib
KW  - BRAF
KW  - metastatic melanoma
KW  - durable response
KW  - clinical practice
KW  - Combination
KW  - Mortality
KW  - Outcomes
KW  - Therapy
KW  - Cohort
KW  - V600e
TI  - Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
TY  - research article
VL  - 14
ER  -